Adjuvant Development for a Thermostable Respiratory Influenza Vaccine

The objective of the proposed project is evaluation of two novel non aluminum vaccine adjuvantsCpG ODN and AdVaxinulin polysaccharidewith intranasal delivery of thermostable live attenuated influenza vaccineLAIVand irradiation inactivation inactivated influenza vaccineIr IIVpowdersThe proposal aims to formulate thermostable vaccines in the dry powder format using patented Preservation by VaporizationPBVtechnologydeliver the vaccines intranasally in a ferret model using a low cost respiratory powder delivery deviceand evaluate the protective efficacy and mucosal immunology induced by each of the adjuvant vaccine combinationsThese studies using influenza as a model vaccine will provide important mechanistic information about inflammatory vsanti inflammatory adjuvants upon intranasal administrationwhile advancing formulations of thermostableadjuvanted respiratory influenza vaccines toward clinical trial and marketThis project seeks to support commercialization of several innovate technologiesnew aluminum free adjuvants with demonstrated safety and efficacyPBV platform technology to enable thermostable biologics for needle free deliveryand an intranasally delivered powder influenza vaccineOutcomes of this study will direct further pre clinical development and commercialization of these promising adjuvants for novel mucosal administrationaddressing the crucial lack of safe and effective adjuvants for human vaccines